Cencora (COR)

NYSE: COR · IEX Real-Time Price · USD
222.60
+0.60 (0.27%)
Jul 12, 2024, 4:00 PM EDT - Market closed
0.27%
Market Cap 44.40B
Revenue (ttm) 276.54B
Net Income (ttm) 1.85B
Shares Out 199.45M
EPS (ttm) 9.15
PE Ratio 24.33
Forward PE 15.75
Dividend $2.04 (0.92%)
Ex-Dividend Date May 9, 2024
Volume 746,665
Open 222.76
Previous Close 222.00
Day's Range 221.81 - 224.09
52-Week Range 171.65 - 246.75
Beta 0.54
Analysts Buy
Price Target 253.17 (+13.73%)
Earnings Date Jul 31, 2024

About COR

Cencora, Inc. sources and distributes pharmaceutical products. The company’s U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institu... [Read more]

Sector Healthcare
Founded 2001
Employees 46,000
Stock Exchange NYSE
Ticker Symbol COR
Full Company Profile

Financial Performance

In 2023, Cencora's revenue was $262.17 billion, an increase of 9.89% compared to the previous year's $238.59 billion. Earnings were $1.75 billion, an increase of 2.74%.

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for COR stock is "Buy." The 12-month stock price forecast is $253.17, which is an increase of 13.73% from the latest price.

Price Target
$253.17
(13.73% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Cencora Announces Date and Time for Third Quarter Fiscal 2024 Earnings Release

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Third Quarter of Fiscal 2024 on Wednesday, July 31, 2024, prior to the openin...

9 days ago - Business Wire

AmerisourceBergen Specialty Group Substitute Notice of Data Incident to Affected Individuals

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--AmerisourceBergen Specialty Group (ABSG) is issuing a substitute notice to individuals who may have been impacted by a data security incident. ABSG's parent company...

5 weeks ago - Business Wire

AmerisourceBergen Specialty Group Provides Substitute Notice of Data Incident to Affected Individuals

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--AmerisourceBergen Specialty Group, LLC (ABSG) is issuing notice to individuals who may have been impacted by a data security incident. ABSG's parent company previou...

7 weeks ago - Business Wire

Cencora notifies individuals about data stolen earlier this year

U.S. drug distributor Cencora has notified affected individuals that their personal and highly sensitive medical information was stolen during a cyberattack and data breach earlier this year, the comp...

7 weeks ago - Reuters

Cencora to buy $400 million in stock back from Walgreens

Cencora has agreed to buy about $400 million in stock back from Walgreens Boots Alliance, the second time the pharmacy chain has reduced its stake in the company this year as it looks to free up cash ...

Other symbols: WBA
7 weeks ago - Market Watch

Cencora Announces Common Share Repurchase From Walgreens Boots Alliance and Raises Fiscal 2024 Guidance

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it has agreed to repurchase shares of its common stock from Walgreens Boots Alliance Holdings LLC in the amount of ap...

7 weeks ago - Business Wire

Walgreens Boots Alliance Sells Shares of Cencora for $400 Million of Proceeds

DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced that it has sold shares of Cencora, Inc. (NYSE: COR) pursuant to a share repurchase by Cencora in the amo...

Other symbols: WBA
7 weeks ago - Business Wire

Cencora To Host Inaugural ThinkLive Cell and Gene Therapy Summit

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, a global healthcare company, will convene leaders from across the healthcare and biopharmaceutical industries for its inaugural ThinkLive Cell and Gene The...

2 months ago - Business Wire

Cencora beats profit estimates on strong demand for costly specialty drugs

Cencora beat Wall Street estimates for second-quarter profit on Wednesday, driven by robust demand for costly specialty medicines that treat complex diseases such as cancer and rheumatoid arthritis.

2 months ago - Reuters

Cencora Reports Fiscal 2024 Second Quarter Results

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today reported that in its fiscal year 2024 second quarter ended March 31, 2024, revenue increased 7.8 percent year-over-year to $68.4 bil...

2 months ago - Business Wire

Cencora Announces Date and Time for Second Quarter Fiscal 2024 Earnings Release

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Second Quarter of Fiscal 2024 on Wednesday, May 1, 2024, prior to the opening...

3 months ago - Business Wire

Cencora Announces Leadership Succession Plan

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that Steven H. Collis will retire as President and Chief Executive Officer of the Company and transition to the role of Ex...

4 months ago - Business Wire

Cencora says hit by cyber attack on its information systems

Cencora Inc said it has learned that data from its information systems had been exfiltrated, some of which may contain personal information, the drug distributor said in a filing on Tuesday.

4 months ago - Reuters

Cencora's FormularyDecisions Launches Payer Resource for Cell and Gene Therapy Products

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--With the increasing number of cell and gene therapy (CGT) products in clinical development, Cencora's FormularyDecisions launched a new resource designed to provide...

5 months ago - Business Wire

Walgreens Boots pockets $992 mln after cutting Cencora stake for third time

U.S. drugstore chain Walgreens Boots Alliance on Wednesday said it has cut its stake in pharmaceutical distributor Cencora for the third time in just over six months, pocketing about $992 million.

Other symbols: WBA
5 months ago - Reuters

Cencora Announces Common Share Repurchase From Walgreens Boots Alliance

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it has agreed to repurchase shares of its common stock from Walgreens Boots Alliance Holdings LLC in the amount of ap...

5 months ago - Business Wire

Walgreens Boots Alliance Sells Shares of Cencora For $992 Million of Proceeds

DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced that it has sold shares of Cencora, Inc. (NYSE: COR) common stock pursuant to Rule 144 for proceeds of ap...

Other symbols: WBA
5 months ago - Business Wire

Cencora Closes $500 Million Senior Notes Offering

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced the closing of its public offering of $500 million aggregate principal amount of its 5.125% Senior Notes due 2034 (the “No...

5 months ago - Business Wire

Cencora Releases 2023 ESG Report

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora (formerly AmerisourceBergen), a global healthcare company, released its 2023 Environmental, Social and Governance (ESG) Report. The report and the related E...

5 months ago - Business Wire

Cencora Prices $500 Million 5.125% Senior Notes Due 2034

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it priced $500 million aggregate principal amount of its 5.125% Senior Notes due 2034 (the “Notes”), in an underwritt...

5 months ago - Business Wire

Cencora raises profit outlook due to robust demand for high-priced specialty drug

Drug distributor Cencora raised its annual profit outlook on Wednesday, betting on strong demand for costly specialty medicines that treat diseases such as cancer and rheumatoid arthritis.

5 months ago - Reuters

Cencora Reports Fiscal 2024 First Quarter Results

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today reported that in its fiscal year 2024 first quarter ended December 31, 2023, revenue increased 15.0 percent year-over-year to $72.3 ...

5 months ago - Business Wire

10 Healthcare Stocks That Are Heating Up

The sector has seen one of the best starts to the year in decades, Goldman says.

6 months ago - Barrons

Cencora Announces Date and Time for First Quarter Fiscal 2024 Earnings Release

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the First Quarter of Fiscal 2024 on Wednesday, January 31, 2024, prior to the ope...

6 months ago - Business Wire

Sapphiros and Cencora, formerly AmerisourceBergen Corporation, Enter into Distribution Agreement

BOSTON , Nov. 22, 2023 /PRNewswire/ -- Sapphiros, a platform company dedicated to building the next generation of consumer diagnostic technologies, is proud to announce it has entered into a distribut...

8 months ago - PRNewsWire